Mode
Text Size
Log in / Sign up

Centralized hair loss measurement showed better agreement and 50% lower error margins than local rating in mild-to-moderate Alopecia AreataCentralized hair loss scoring showed better consistency than local ratings in mild Alopecia Areata trials

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that centralized hair loss measurement offers superior consistency and lower error margins compared to local rating in mild-to-moderate Alopecia Areata.

This Phase 2 clinical trial evaluated the repeatability and reproducibility of hair loss assessment methods in patients with mild-to-moderate Alopecia Areata, defined as hair loss of 50% or less. The study compared a centralized measurement system utilizing professional camera equipment and a standardized protocol against local SALT score ratings performed at trial sites. The primary outcomes focused on scoring agreement, consistency, margins of error, and the impact of each method on clinical endpoints.

The analysis demonstrated good agreement and consistency when using the central rating system. Margins of error were 50% lower with the central rating compared to local ratings. Furthermore, substituting the local rating system for the central rating resulted in a reduction of the likelihood of achieving a statistically significant outcome, with the magnitude of this reduction being at least 50% depending on the specific SALT score-defined clinical response endpoint used.

No safety data, including adverse events or tolerability, were reported in this study. A key limitation identified was the potential for inter-rater variability and margin of error inherent in local scoring for mild-to-moderate Alopecia Areata, which may compromise results. Consequently, the practice relevance suggests that centralized rating is most appropriate during the Phase 2 learning stage of clinical development, while local scoring may introduce variability that affects outcome interpretation.

Researchers conducted a Phase 2 clinical trial to compare two methods for measuring hair loss in patients with mild-to-moderate Alopecia Areata, defined as 50% or less hair loss. One method used centralized measurement from photographic images taken with standardized professional equipment, while the other relied on local ratings performed at the trial sites.

The results showed that the centralized rating system achieved good agreement and consistency. It produced margins of error that were 50% lower than the local rating system. However, substituting the local rating for the central rating would reduce the likelihood of achieving a statistically significant outcome by at least 50%, depending on the specific clinical response endpoint used.

No safety concerns were reported in this study, as adverse events and tolerability were not reported. The main reason to be careful is that potential inter-rater variability and margin of error in local scoring for mild-to-moderate Alopecia Areata may compromise results. Readers should understand that this study is in the early learning stage of clinical development, where centralized rating is most appropriate. This evidence does not yet support changing standard practice outside of this specific trial phase.

What this means for you:
Centralized hair loss scoring had lower error than local ratings in this early trial of mild Alopecia Areata.

Study Details

Study typePhase2
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Background In clinical trials for alopecia areata (AA) the treatment effect (percentage of hair loss) is estimated using the Severity of Alopecia Tool (SALT) score. Trials in patients with severe AA (>=50% hair loss) employed a local rating of the SALT score performed at trial sites by different investigators. However, in mild-to-moderate AA (<= 50% hair loss) where SALT scores are lower, potential inter rater variability and margin of error may compromise the results. Objectives To compare Centralised and Local measurement of hair loss in mild moderate AA. Methods In a Phase 2 clinical trial a centralised measurement of hair loss was performed from photographic images taken using a standardised protocol and professional camera equipment. Local scoring was also undertaken at screening/baseline for eligibility. We assessed: the repeatability of the central system (screening vs baseline values), the reproducibility of the central versus the local rating system and the potential impact of each method on the endpoints using a Monte-Carlo simulation method. Results There was good agreement and consistency of scoring with Central rating. This provided much smaller margins of error, 50% lower than Local rating. The simulations demonstrated that substituting Local rating for Central rating would result in a reduction of the likelihood of a statistically significant outcome by at least 50% depending on the SALT score defined clinical response endpoint. Conclusions Central rating is most appropriate in the Phase 2 learning stage of clinical development and provides an accurate representation of the quantity of hair loss, minimising error and ensuring consistency in measurements.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.